Industry
Medical - Healthcare Information Services
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
Loading...
Open
28.62
Mkt cap
574M
Volume
340K
High
29.79
P/E Ratio
58.33
52-wk high
51.22
Low
28.45
Div yield
0.01
52-wk low
27.07
Portfolio Pulse from
November 22, 2024 | 1:30 pm
Portfolio Pulse from
November 08, 2024 | 4:00 pm
Portfolio Pulse from Benzinga Newsdesk
October 30, 2024 | 12:33 pm
Portfolio Pulse from Benzinga Newsdesk
October 24, 2024 | 6:56 pm
Portfolio Pulse from Benzinga Newsdesk
October 24, 2024 | 4:16 pm
Portfolio Pulse from Benzinga Newsdesk
October 24, 2024 | 4:01 pm
Portfolio Pulse from Benzinga Newsdesk
October 23, 2024 | 8:25 pm
Portfolio Pulse from Benzinga Newsdesk
October 23, 2024 | 8:20 pm
Portfolio Pulse from Benzinga Insights
October 22, 2024 | 7:02 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.